Outline of the Training School

The training school aims to give insights into drug discovery and development. The core of the course is an interactive and group discussion simulation of a drug discovery project from discovering to launching a new medicine (day 2 and 3). Each participant will be assigned a role in the project team and need to come prepared to the course. Participants will encounter and make decisions about various scientific challenges and possible research path. The team will choose a therapeutic indication and drug target, search for potential chemical leads, optimize and progress these leads through preclinical research, demonstrating that selected drug candidate is safe and effective in patients, advance the drug through clinical trials, and ultimately submit the drug for registration with health authorities. To prepare participants for this interactive course they will get an introduction into preclinical and clinical drug discovery and development and also meet with experts to discuss their assigned roles (day 1).

Organisers:
- Anne-Ulrike Trendelenburg, Unit Head, Muscle Research, Novartis
- Ronald van Os, University of Groningen, Netherlands
- Ana Luisa Cardoso, University of Coimbra, Portugal

[Image credit: Novartis]
Trainers

- Anne-Ulrike Trendelenburg, Unit Head, Muscle Research, Novartis
- Ronald van Os, University of Groningen, Netherlands
- Ana Luisa Cardoso, University of Coimbra, Portugal
- Michaela Kneissel, Head of Research, Musculoskeletal Disease, Novartis
- Estelle Trifilieff, Unit Head, Muscle Research, Novartis
- Ronenn Roubenoff, Head Translational Medicine, Musculoskeletal disease, Novartis
- Fernando Romero, Learning Partner, Scientific & Team Excellence, NIBR, Novartis
- Felicitas Thom, Head of Clinical Sciences – Musculoskeletal Disease and Dermatology, Clinical Sciences & Innovation, NIBR, Novartis

Wednesday 4th October 2017

‘Introduction and meet the scientists’
Room: Fabrikstrasse 16.22 Auditoria

Introduction

- Opening: Michaela Kneissel, Head of Research, Musculoskeletal Disease, Novartis
- Preclinical research: Estelle Trifilieff, Unit Head, Muscle Research, Novartis
- Clinical research: Ronenn Roubenoff, Head Translational Medicine, Musculoskeletal disease, Novartis

Meet the scientists

Musculoskeletal Disease area (MSD) line function representatives will be available to answer questions and further discuss assigned roles in the simulation.

Thursday 5th & Friday 6th October 2017

Interactive project simulation

09:00 – 17:00 Drug Discovery and Development (D3) simulation
Fernando Romero, Learning Partner, Scientific & Team Excellence, Novartis
Felicitas Thom, Clinical Scientist Head, Clinical Sciences & Innovation, Novartis
Room: Fabrikstrasse 16.P15 and P.17
Upon completion of the course, participants will be able to:

- Explain and discuss unmet medical need, knowledge of mechanism, disease opportunities, and other factors considered when evaluating/pursuing a therapeutic target
- Describe in general terms the stages of drug discovery and development and what activities typically occur in those stages
- Explain the contribution of different scientific/clinical disciplines to drug discovery and development
- Propose and justify key elements of decision-making studies, both pre-clinical and clinical, and recognize the importance of identifying the critical path unique to each project necessary to move it forward
- Recognize and discuss challenges a project team may encounter in their mission to discover and develop a new drug